Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.
Name:
s00330-017-4972-z.pdf
Size:
1.827Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
deSouza, NWinfield, J
Waterton, John C
Weller, A
Papoutsaki, M-V
Doran, S
Collins, D
Fournier, L
Sullivan, D
Chenevert, T
Jackson, Alan
Boss, M
Trattnig, S
Liu, Y
Affiliation
CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UK. Nandita.Desouza@icr.ac.ukCRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UKManchester Academic Health Sciences Institute, University of Manchester, Manchester, UKCRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UKCRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UKCRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UKCRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UKAssistance Publique-Hopitaux de Paris, Hopital Europeen Georges Pompidou, Radiology Department, Universite Paris Descartes Sorbonne Paris Cite, Paris, FranceDuke Comprehensive Cancer Institute, Durham, NC, USADepartment of Radiology, University of Michigan Health System, Ann Arbor, MI, USAManchester Academic Health Sciences Institute, University of Manchester, Manchester, UKApplied Physics Division, National Institute of Standards and Technology (NIST), Boulder, CO, USADepartment of Biomedical Imaging and Image guided Therapy, Medical University of Vienna, 1090, Vienna, AustriaEuropean Organisation for Research and Treatment of Cancer, Headquarters, Brussels, BelgiumIssue Date
2017-09-27
Metadata
Show full item recordAbstract
For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of the apparent diffusion coefficient (ADC) is required. Validation and qualification of ADC in multicentre trials involves examination of i) technical performance to determine biomarker bias and reproducibility and ii) biological performance to interrogate a specific aspect of biology or to forecast outcome. Unfortunately, the variety of acquisition and analysis methodologies employed at different centres make ADC values non-comparable between them. This invalidates implementation in multicentre trials and limits utility of ADC as a biomarker. This article reviews the factors contributing to ADC variability in terms of data acquisition and analysis. Hardware and software considerations are discussed when implementing standardised protocols across multi-vendor platforms together with methods for quality assurance and quality control. Processes of data collection, archiving, curation, analysis, central reading and handling incidental findings are considered in the conduct of multicentre trials. Data protection and good clinical practice are essential prerequisites. Developing international consensus of procedures is critical to successful validation if ADC is to become a useful biomarker in oncology.Citation
Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives. 2017, Eur RadiolJournal
European RadiologyDOI
10.1007/s00330-017-4972-zPubMed ID
28956113Type
ArticleLanguage
enISSN
1432-1084ae974a485f413a2113503eed53cd6c53
10.1007/s00330-017-4972-z
Scopus Count
Collections
Related articles
- Assessment and quantification of sources of variability in breast apparent diffusion coefficient (ADC) measurements at diffusion weighted imaging.
- Authors: Giannotti E, Waugh S, Priba L, Davis Z, Crowe E, Vinnicombe S
- Issue date: 2015 Sep
- Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
- Authors: Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators
- Issue date: 2019 Jun
- Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.
- Authors: Michoux NF, Ceranka JW, Vandemeulebroucke J, Peeters F, Lu P, Absil J, Triqueneaux P, Liu Y, Collette L, Willekens I, Brussaard C, Debeir O, Hahn S, Raeymaekers H, de Mey J, Metens T, Lecouvet FE
- Issue date: 2021 Jul
- Technical Note: A safe, cheap, and easy-to-use isotropic diffusion MRI phantom for clinical and multicenter studies.
- Authors: Pullens P, Bladt P, Sijbers J, Maas AI, Parizel PM
- Issue date: 2017 Mar
- Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force.
- Authors: Sedlaczek OL, Kleesiek J, Gallagher FA, Murray J, Prinz S, Perez-Lopez R, Sala E, Caramella C, Diffetock S, Lassau N, Priest AN, Suzuki C, Vargas R, Giandini T, Vaiani M, Messina A, Blomqvist LK, Beets-Tan RGH, Oberrauch P, Schlemmer HP, Bach M, CCE – Imaging Task Force
- Issue date: 2022 Dec